NEW YORK (GenomeWeb) – The American Society of Clinical Oncology published revised early-stage breast cancer guidelines today that feature a focused update recommending Agendia's MammaPrint for guiding treatment decisions in early stage breast cancer patients with 1-to-3 positive lymph nodes.

According to the company, the revision is the fourth this year regarding MammaPrint, and is supported by data from the randomized, prospective, Phase III MINDACT trial, which was published last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.